In vivo effects of APP are not exacerbated by BACE2 co-overexpression: behavioural characterization of a double transgenic mouse model

Amino Acids ◽  
2010 ◽  
Vol 39 (5) ◽  
pp. 1571-1580 ◽  
Author(s):  
Garikoitz Azkona ◽  
Ditsa Levannon ◽  
Yoram Groner ◽  
Mara Dierssen
Keyword(s):  
Mouse Model ◽  
Transgenic Mouse ◽  
Transgenic Mouse Model ◽  
Double Transgenic Mouse ◽  
In Vivo Effects

scholarly journals Biochemical and behavioral characterization of the double transgenic mouse model (APPswe/PS1dE9) of Alzheimer’s disease

2011 ◽  
Vol 27 (4) ◽  
pp. 221-232 ◽  
Author(s):  
Huaqi Xiong ◽  
Debbie Callaghan ◽  
Jolanta Wodzinska ◽  
Jiejing Xu ◽  
Maryna Premyslova ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mouse Model ◽  
Transgenic Mouse ◽  
Transgenic Mouse Model ◽  
Double Transgenic Mouse ◽  
Behavioral Characterization

scholarly journals The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model

Blood ◽  
2010 ◽  
Vol 115 (16) ◽  
pp. 3341-3345 ◽  
Author(s):  
Ke Cheng ◽  
Paolo Sportoletti ◽  
Keisuke Ito ◽  
John G. Clohessy ◽  
Julie Teruya-Feldstein ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Mouse Model ◽  
Transgenic Mice ◽  
Transgenic Mouse ◽  
Myeloid Leukemia ◽  
Gene Mutations ◽  
Transgenic Mouse Model ◽  
Acute Myeloid

Abstract Although NPM1 gene mutations leading to aberrant cytoplasmic expression of nucleophosmin (NPMc+) are the most frequent genetic lesions in acute myeloid leukemia, there is yet no experimental model demonstrating their oncogenicity in vivo. We report the generation and characterization of a transgenic mouse model expressing the most frequent human NPMc+ mutation driven by the myeloid-specific human MRP8 promoter (hMRP8-NPMc+). In parallel, we generated a similar wild-type NPM trans-genic model (hMRP8-NPM). Interestingly, hMRP8-NPMc+ transgenic mice developed myeloproliferation in bone marrow and spleen, whereas nontransgenic littermates and hMRP8-NPM transgenic mice remained disease free. These findings provide the first in vivo evidence indicating that NPMc+ confers a proliferative advantage in the myeloid lineage. No spontaneous acute myeloid leukemia was found in hMPR8-NPMc+ or hMRP8-NPM mice. This model will also aid in the development of therapeutic regimens that specifically target NPMc+.

scholarly journals Establishment and Characterization of a Transgenic Mouse Model for In Vivo Imaging of Bmp4 Expression in the Pancreas

PLoS ONE ◽  
2011 ◽  
Vol 6 (9) ◽  
pp. e24956 ◽  
Author(s):  
Mayu Yasunaga ◽  
Nao Oumi ◽  
Mitsuhiko Osaki ◽  
Yasuhiro Kazuki ◽  
Tomoko Nakanishi ◽  
...  
Keyword(s):  
Mouse Model ◽  
Transgenic Mouse ◽  
In Vivo Imaging ◽  
Transgenic Mouse Model ◽  
Bmp4 Expression

In vivo characterization of endothelial cell activation in a transgenic mouse model of Alzheimer’s disease

Angiogenesis ◽  
2006 ◽  
Vol 9 (2) ◽  
pp. 59-65 ◽  
Author(s):  
Caroline Schultheiss ◽  
Birgit Blechert ◽  
Florian C. Gaertner ◽  
Enken Drecoll ◽  
Jan Mueller ◽  
...  
Keyword(s):  
Endothelial Cell ◽  
Mouse Model ◽  
Transgenic Mouse ◽  
Cell Activation ◽  
Transgenic Mouse Model ◽  
Endothelial Cell Activation ◽  
Model Of Alzheimer’S Disease ◽  
In Vivo Characterization

scholarly journals Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects

2021 ◽  
Author(s):  
Madeleine F. Jennewein ◽  
Anna J. MacCamy ◽  
Nicholas R. Akins ◽  
Junli Feng ◽  
Leah J. Homad ◽  
...  
Keyword(s):  
Mouse Model ◽  
Transgenic Mouse ◽  
Neutralizing Antibodies ◽  
Transgenic Mouse Model ◽  
Human Coronavirus ◽  
Epitope Specificity ◽  
The Past ◽  
Isolation And Characterization

SUMMARYSARS-CoV-2 is one of three coronaviruses that have crossed the animal-to-human barrier in the past two decades. The development of a universal human coronavirus vaccine could prevent future pandemics. We characterized 198 antibodies isolated from four COVID19+ subjects and identified 14 SARS-CoV-2 neutralizing antibodies. One targeted the NTD, one recognized an epitope in S2 and twelve bound the RBD. Three anti-RBD neutralizing antibodies cross-neutralized SARS-CoV-1 by effectively blocking binding of both the SARS-CoV-1 and SARS-CoV-2 RBDs to the ACE2 receptor. Using the K18-hACE transgenic mouse model, we demonstrate that the neutralization potency rather than the antibody epitope specificity regulates the in vivo protective potential of anti-SARS-CoV-2 antibodies. The anti-S2 antibody also neutralized SARS-CoV-1 and all four cross-neutralizing antibodies neutralized the B.1.351 mutant strain. Thus, our study reveals that epitopes in S2 can serve as blueprints for the design of immunogens capable of eliciting cross-neutralizing coronavirus antibodies.

Metabolic Characterization of the R6/2 Transgenic Mouse Model of Huntington's Disease by High-Resolution MAS1H NMR Spectroscopy

2006 ◽  
Vol 5 (3) ◽  
pp. 483-492 ◽  
Author(s):  
Tsz M. Tsang ◽  
Ben Woodman ◽  
Gerard A. Mcloughlin ◽  
Julian L. Griffin ◽  
Sarah J. Tabrizi ◽  
...  
Keyword(s):  
Nmr Spectroscopy ◽  
High Resolution ◽  
Mouse Model ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Transgenic Mouse ◽  
Transgenic Mouse Model
Sign in / Sign up

Export Citation Format

Share Document